NEW YORK, Dec. 11 - Atugen of Berlin said Tuesday it had signed a deal to validate gene targets for Oxford GlycoSciences.

Under the terms of the deal, OGS of Oxford, UK, will provide targets to Atugen, which will validate them using its animal models.

Atugen has developed a technology called GeneBloc, which is designed to block protein production, enabling the company to determine gene function.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.